Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
35
SUPN Quote, Financials, Valuation and Earnings
Last price:
$45.07
Seasonality move
:
-0.27%
Day range:
$44.28 - $45.10
52-week range:
$29.16 - $57.65
Dividend yield:
0%
P/E ratio:
41.17x
P/S ratio:
3.70x
P/B ratio:
2.45x
Volume:
527.5K
Avg. volume:
1M
1-year change:
20.88%
Market cap:
$2.6B
Revenue:
$661.8M
EPS (TTM):
-$0.34
Analysts' Opinion
-
Consensus RatingSupernus Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $60.50, Supernus Pharmaceuticals, Inc. has an estimated upside of 35.17% from its current price of $44.76.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $50.00 representing -11.71% downside risk from its current price of $44.76.
Fair Value
-
According to the consensus of 5 analysts, Supernus Pharmaceuticals, Inc. has 35.17% upside to fair value with a price target of $60.50 per share.
SUPN vs. S&P 500
-
Over the past 5 trading days, Supernus Pharmaceuticals, Inc. has underperformed the S&P 500 by -2.87% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Supernus Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Supernus Pharmaceuticals, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Supernus Pharmaceuticals, Inc. reported revenues of $192.1M.
Earnings Growth
-
Supernus Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Supernus Pharmaceuticals, Inc. reported earnings per share of -$0.80.
Enterprise value:
2.3B
EV / Invested capital:
2.13x
Price / LTM sales:
3.70x
EV / EBIT:
32.38x
EV / Revenue:
3.42x
PEG ratio (5yr expected):
0.03x
EV / Free cash flow:
32.90x
Price / Operating cash flow:
35.67x
Enterprise value / EBITDA:
44.38x
Gross Profit (TTM):
$518.5M
Return On Assets:
-1.37%
Net Income Margin (TTM):
-2.81%
Return On Equity:
-1.84%
Return On Invested Capital:
-1.78%
Operating Margin:
-31.77%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $610.5M | $652M | $681.5M | $175.7M | $192.1M | |
| Gross Profit | $438.9M | $497.3M | $518.5M | $138M | $148.3M | |
| Operating Income | $26.3M | $72.8M | -$32.9M | $39.8M | -$61M | |
| EBITDA | $110.9M | $156M | $52.4M | $59.9M | -$36.2M | |
| Diluted EPS | $0.39 | $1.07 | -$0.34 | $0.69 | -$0.80 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $668.4M | $663.9M | $449.4M | $640M | $593.9M | |
| Total Assets | $1.6B | $1.7B | $1.3B | $1.3B | $1.4B | |
| Current Liabilities | $234.7M | $726M | $287.5M | $291.5M | $330.6M | |
| Total Liabilities | $744.6M | $840.3M | $373M | $335.6M | $370.1M | |
| Total Equity | $810.5M | $852.8M | $912.2M | $1B | $1B | |
| Total Debt | $426.1M | $36M | $33.8M | $28.9M | $31.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $93.7M | $172.5M | $71.9M | $53.5M | -$61.7M | |
| Cash From Investing | $285.9M | -$243.2M | $42.8M | -$77M | $48.7M | |
| Cash From Financing | -$396.1M | $7.4M | $6.5M | $3.1M | $21.1M | |
| Free Cash Flow | $93.1M | $172M | $70.8M | $53.3M | -$61.8M | |
SUPN
Sector
Market Cap
$2.6B
$28.4M
Price % of 52-Week High
77.64%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-1.33%
-1.32%
1-Year Price Total Return
20.88%
-22.19%
Beta (5-Year)
0.715
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$45.25
200-day SMA
Buy
Level
$38.44
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$45.42
Relative Strength Index (RSI14)
Sell
Level
42.74
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-75.9322
50-day SMA
Sell
Level
$48.46
MACD (12, 26)
Sell
Level
-1.18
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.0102)
Buy
CA Score
(Annual)
Level (0.6959)
Buy
Beneish M-Score
(Annual)
Level (-2.8392)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-2.3254)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Stock Forecast FAQ
In the current month, SUPN has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The SUPN average analyst price target in the past 3 months is $60.50.
-
Where Will Supernus Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Supernus Pharmaceuticals, Inc. share price will rise to $60.50 per share over the next 12 months.
-
What Do Analysts Say About Supernus Pharmaceuticals, Inc.?
Analysts are divided on their view about Supernus Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Supernus Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $50.00.
-
What Is Supernus Pharmaceuticals, Inc.'s Price Target?
The price target for Supernus Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $60.50 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is SUPN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Supernus Pharmaceuticals, Inc. is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SUPN?
You can purchase shares of Supernus Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Supernus Pharmaceuticals, Inc. shares.
-
What Is The Supernus Pharmaceuticals, Inc. Share Price Today?
Supernus Pharmaceuticals, Inc. was last trading at $45.07 per share. This represents the most recent stock quote for Supernus Pharmaceuticals, Inc.. Yesterday, Supernus Pharmaceuticals, Inc. closed at $44.76 per share.
-
How To Buy Supernus Pharmaceuticals, Inc. Stock Online?
In order to purchase Supernus Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SUPN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SUPN
Sector
P/E ratio
41.17x
23.66x
PEG ratio
0.03x
-0.01x
P/B ratio
2.45x
1.84x
Price / LTM sales
3.70x
1.60x
Growth Metrics
SUPN
Sector
Revenue growth
9.34%
4.85%
Earnings growth
-216.09%
11.15%
Revenue (5-year growth)
11%
6.45%
Earnings forecast
$0.82
-$0.20
Profitability
SUPN
Sector
Profitability FY 2024
$503.5M
$3.6M
Return on invested capital
-1.78%
-30.98%
Return on assets
-1.37%
-27.62%
Return on equity
-1.84%
-36.69%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Feb
3
Balance Sheet
SUPN
Sector
Total cash
$281.2M
$27.2M
Short term investments
$384.3M
$25.7M
Total assets
$1.5B
$79.9M
Long term debt
$31.4M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
